

PATENT



## THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Alexander Gaiger et al.  
 Application No. : 09/785,019  
 Filed : February 15, 2001  
 For : COMPOSITIONS AND METHODS FOR WT1 SPECIFIC  
 IMMUNOTHERAPY

Docket No. : 210121.465C4  
 Examiner : Ronald B. Schwadron, Ph.D.  
 Art Unit : 1644  
 Date : November 18, 2005

Mail Stop AF  
 Commissioner for Patents  
 P.O. Box 1450  
 Alexandria, VA 22313-1450

REQUEST TO CORRECT INVENTORSHIP UNDER 37 CFR 1.48(b)


We hereby request a correction of the inventorship of the above-identified utility application pursuant to 37 CFR 1.48(b). Please remove Patricia D. McNeill, Molly Smithgall, Gus Moulton, Thomas S. Vedvick, and Paul R. Sleath as inventors.

The order of the inventorship should read: **Alexander Gaiger, Martin A. Cheever.**

The inventorship changes occurred due to amendments and/or cancellation of claims and without deceptive intent on the part of the remaining inventors. A check for the requisite processing fee of \$130.00 is enclosed.

Respectfully submitted,

Seed Intellectual Property Law Group PLLC

  
 Julie A. Urvater, Ph.D., Patent Agent  
 Registration No. 50,461

701 Fifth Avenue, Suite 6300  
 Seattle, Washington 98104-7092  
 (206) 622-4900  
 Fax: (206) 682-6031

Best Available Copy,

11/23/2005 CNGUYEN 00000036 09785019

03 FC:1464

130.00 DP



EXPRESS MAIL NO. EV530944736US

PTO/SB/01A (09-04).

Approved for use through 03/31/2008. OMB 0851-0032.

U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**DECLARATION (37 CFR 1.63) FOR UTILITY OR DESIGN APPLICATION  
USING AN APPLICATION DATA SHEET (37 CFR 1.76)****Title of Invention** COMPOSITIONS AND METHODS FOR WT1 SPECIFIC  
IMMUNOTHERAPY

As the below named inventor(s), I/we declare that:

This declaration is directed to:

- ☐ The attached application, or  
☒ Application No. 09/785,019, filed on February 15, 2001,  
☒ as amended on October 14, 2004 (if applicable);

I/we believe that I/we am/are the original and first inventor(s) of the subject matter which is claimed and for which a patent is sought;

I/we have reviewed and understand the contents of the above-identified application, including the claims, as amended by any amendment specifically referred to above;

I/we acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me/us to be material to patentability as defined in 37 CFR 1.56, including for continuation-in-part applications, material information which became available between the filing date of the prior application and the national or PCT International filing date of the continuation-in-part application.

All statements made herein of my/our own knowledge are true, all statements made herein on information and belief are believed to be true, and further that these statements were made with the knowledge that willful false statements and the like are punishable by fine or imprisonment, or both, under 18 U.S.C. 1001, and may jeopardize the validity of the application or any patent issuing thereon.

**FULL NAME OF INVENTOR(S)**Inventor one: Alexander Gaiger Citizen of: Austria

Signature: \_\_\_\_\_ Date: \_\_\_\_\_

Inventor two: Martin A. Cheever Citizen of: USSignature: Martin A. Cheever Date: 13 OCT 2005

Inventor three: \_\_\_\_\_ Citizen of: \_\_\_\_\_

Signature: \_\_\_\_\_ Date: \_\_\_\_\_

Inventor four: \_\_\_\_\_ Citizen of: \_\_\_\_\_

Signature: \_\_\_\_\_ Date: \_\_\_\_\_

☐ Additional inventors or a legal representative are being named on \_\_\_\_\_ additional form(s) attached hereto.

This collection of information is required by 35 U.S.C. 115 and 37 CFR 1.63. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 1 minute to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450. C:\NRP\Monago\MONICA\SA1694835\_1.DOC



EXPRESS MAIL NO. EV530944736US

U.S. Patent and Trademark Office, U.S. Department of Commerce

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**DECLARATION (37 CFR 1.63) FOR UTILITY OR DESIGN APPLICATION  
USING AN APPLICATION DATA SHEET (37 CFR 1.76)**

Title of Invention	COMPOSITIONS AND METHODS FOR WT1 SPECIFIC IMMUNOTHERAPY
--------------------	---

As the below named inventor(s), I/we declare that:

This declaration is directed to:

- ☐ The attached application, or  
☒ Application No. 09/785,019, filed on February 15, 2001,  
☒ as amended on October 14, 2004 (if applicable);

I/we believe that I/we am/are the original and first inventor(s) of the subject matter which is claimed and for which a patent is sought;

I/we have reviewed and understand the contents of the above-identified application, including the claims, as amended by any amendment specifically referred to above;

I/we acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me/us to be material to patentability as defined in 37 CFR 1.56, including for continuation-in-part applications, material information which became available between the filing date of the prior application and the national or PCT International filing date of the continuation-in-part application.

All statements made herein of my/our own knowledge are true, all statements made herein on information and belief are believed to be true, and further that these statements were made with the knowledge that willful false statements and the like are punishable by fine or imprisonment, or both, under 18 U.S.C. 1001, and may jeopardize the validity of the application or any patent issuing thereon.

**FULL NAME OF INVENTOR(S)**Inventor one: Alexander GaigerCitizen of: AustriaSignature: *Alexander Gaiger*Date: 16 Oct 2005Inventor two: Martin A. ChoeverCitizen of: US

Signature: \_\_\_\_\_

Date: \_\_\_\_\_

Inventor three: \_\_\_\_\_

Citizen of: \_\_\_\_\_

Signature: \_\_\_\_\_

Date: \_\_\_\_\_

Inventor four: \_\_\_\_\_

Citizen of: \_\_\_\_\_

Signature: \_\_\_\_\_

Date: \_\_\_\_\_

☐ Additional inventors or a legal representative are being named on \_\_\_\_\_ additional form(s) attached hereto.

This collection of information is required by 35 U.S.C. 115 and 37 CFR 1.63. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 1 minute to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

C:\N:\Form\Atm\atm\CA16094835 1.DOC

Best Available Copy



EXPRESS MAIL NO. EV530944736US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Alexander Gaiger et al.  
Application No. : 09/785,019  
Filed : February 15, 2001  
For : COMPOSITIONS AND METHODS FOR WT1 SPECIFIC  
IMMUNOTHERAPY

Examiner : Ronald B. Schwadron, Ph.D.  
Art Unit : 1644  
Docket No. : 210121.465C4

Mail Stop AF  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

DECLARATION OF ALEXANDER GAIGER AND MARTIN A. CHEEVER

Commissioner for Patents,

We, Alexander Gaiger and Martin A. Cheever, declare and state that:


1. We are the joint inventions in the above-identified application.
2. We are co-authors, along with Valerie Reese and Mary L. Disis, of an article entitled "Immunity to WT1 in the Animal Model and in Patients With Acute Myeloid Leukemia," Blood, 15 August 2000, 96(4):1480-1489 (hereinafter referred to as the "Gaiger *et al.* article").
3. We are familiar with the development of the subject matter described in the Gaiger *et al.* article.
4. Valerie Reese worked as a technician in our laboratory and, under our direction and supervision, she assisted in experiments associated with the Gaiger *et*


Best Available Copy

5. Mary L. Disis provided technical guidance on the immune response assays used in this study.

6. As a result of the participation and capacity recited in paragraphs 4 and 5 above, the substance of the Gaiger *et al.* article was the work of only us.

7. We further declare that all statements made herein of our own knowledge are true, and that all statements made on information and belief are believed to be true, and further, that these statements were made with the knowledge that willful, false statements, and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code.

  
\_\_\_\_\_  
Alexander Gaiger, Ph.D.

  
\_\_\_\_\_  
Date

\_\_\_\_\_  
Martin A. Cheever, Ph.D.

\_\_\_\_\_  
Date

Best Available Copy



EXPRESS MAIL NO. EV530944736US

PATENT

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Alexander Gaiger et al.  
Application No. : 09/785,019  
Filed : February 15, 2001  
For : COMPOSITIONS AND METHODS FOR WT1 SPECIFIC  
IMMUNOTHERAPY

Examiner : Ronald B. Schwadron, Ph.D.  
Art Unit : 164  
Docket No. : 210 21.465C4

Mail Stop AF  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

## DECLARATION OF ALEXANDER GAIGER AND MARTIN A. CHEEVER

Commissioner for Patents,

We, Alexander Gaiger and Martin A. Cheever, declare and state that:

1. We are the joint inventors in the above-identified application.
2. We are co-authors, along with Valerie Recse and Mary L. Disis, of an article entitled "Immunity to WT1 in the Animal Model and in Patients With Acute Myeloid Leukemia," Blood, 15 August 2000, 96(4):1480-1489; hereinafter referred to as the "Gaiger *et al.* article").
3. We are familiar with the development of the subject matter described in the Gaiger *et al.* article.
4. Valerie Recse worked as a technician in our laboratory and, under our direction and supervision, she assisted in experiments associated with the Gaiger *et al.* article.

Best Available Copy


5. Mary L. Disis provided technical guidance on the immune response assays used in this study.

6. As a result of the participation and capacity recited in paragraphs 4 and 5 above, the substance of the Gaiger *et al.* article was the work of only us.

7. We further declare that all statements made herein of our own knowledge are true, and that all statements made on information and belief are believed to be true, and further, that those statements were made with the knowledge that willful, false statements, and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code.

Alexander Gaiger, Ph.D.

Date

  
Martin A. Cheever, Ph.D.

13 Oct 2005  
Date

Best Available Copy